# Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma

> **NCT00228488** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 60 (—)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT00228488
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** —
- **Final completion:** 2005-12
- **Target enrollment:** 60 (—)
- **Last updated:** 2007-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00228488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00228488, "Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00228488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*